Journal Article
. 2011 Jul; 6(3):234-239.
doi: 10.1159/000328964.

Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer

Cornelia Liedtke 1 Ludwig Kiesel  
Affiliations
  • PMID: 21779231
  •     12 References
  •     6 citations

Abstract

Patients with triple-negative breast cancer are characterized by a poor prognosis compared with patients with other breast cancer subtypes. The angiogenesis inhibitor bevacizumab is effective in the palliative treatment of patients with triple-negative breast cancer as well as in other breast cancer subtypes. PARP inhibitors represent the first group of targeted agents to be developed under the particular aspect of treating patients with hereditary and triple-negative breast cancer. In addition, an increasing number of studies have demonstrated a significant and clinically relevant change in phenotype between primary tumor and metastasis. Consequently, it should be an essential component of the design of modern clinical trials of targeted agents in metastatic breast cancer to determine the relevant tumor phenotype and, depending on the clinical situation, confirm the presence of the therapeutic target in metastatic lesions.

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
Robert Gray, Suman Bhattacharya, +2 authors, Robert L Comis.
J Clin Oncol, 2009 Sep 02; 27(30). PMID: 19720913    Free PMC article.
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
C Liedtke, K Broglio, +11 authors, A M Gonzalez-Angulo.
Ann Oncol, 2009 Jul 15; 20(12). PMID: 19596702    Free PMC article.
Highly Cited.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, +12 authors, James Carmichael.
Lancet, 2010 Jul 09; 376(9737). PMID: 20609467
Highly Cited.
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey, Eric Winer, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2010 Sep 30; 7(12). PMID: 20877296
Highly Cited. Review.
Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Dorothea Gadzicki, Alexandra Schubert, +6 authors, Brigitte Schlegelberger.
Cancer Genet Cytogenet, 2009 Feb 14; 189(2). PMID: 19215791
Triple-negative breast cancer--current status and future directions.
O Gluz, C Liedtke, +3 authors, N Harbeck.
Ann Oncol, 2009 Nov 11; 20(12). PMID: 19901010
Highly Cited. Review.
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.
B K Linderholm, H Hellborg, +4 authors, R Lewensohn.
Ann Oncol, 2009 Jun 25; 20(10). PMID: 19549711
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Jonas Bergh, Igor M Bondarenko, +12 authors, Carla Giorgetti.
J Clin Oncol, 2012 Feb 15; 30(9). PMID: 22331954
Highly Cited.
Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth.
Nat Rev Cancer, 2004 Oct 29; 4(10). PMID: 15510162
Highly Cited. Review.
BRCA1 dysfunction in sporadic basal-like breast cancer.
N C Turner, J S Reis-Filho, +8 authors, A N Tutt.
Oncogene, 2006 Oct 04; 26(14). PMID: 17016441
Highly Cited.
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, +5 authors, Banu K Arun.
J Clin Oncol, 2008 Sep 10; 26(26). PMID: 18779615    Free PMC article.
Highly Cited.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.
Kun-Ming Rau, Chao-Cheng Huang, +5 authors, Yu-Ching Wei.
Exp Ther Med, 2012 Nov 10; 4(2). PMID: 23139713    Free PMC article.
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.
M Mancini, M B Gariboldi, +4 authors, E Monti.
Br J Cancer, 2014 May 24; 110(12). PMID: 24853185    Free PMC article.
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Zhiwei Hu, Rulong Shen, +6 authors, William E Carson.
Cancer Immunol Res, 2018 Apr 07; 6(6). PMID: 29622581    Free PMC article.
FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control.
Xiaofeng Dai, Shuo Zhang, +3 authors, Zhaohui Huang.
Front Oncol, 2019 Nov 12; 9. PMID: 31709178    Free PMC article.
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
Zhiwei Hu.
Sci Rep, 2020 Feb 20; 10(1). PMID: 32071339    Free PMC article.